Argenx VYVGART Data Boosts Stock Target to EUR 982.00

Argenx (ISIN NL0010832176) presented new data on its drug VYVGART at scientific sessions on September 29, 2026. The data covered treatments for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and other pipeline programs. A real-world analysis of over 1,100 U.S. patients showed that earlier VYVGART treatment led to better symptom outcomes, reduced steroid use, and fewer exacerbations. Notably, patients who started VYVGART within one year of diagnosis saw a mean MG-ADL reduction of 4.70 points in the first three months, compared to 3.50 points for those treated more than three years after diagnosis.

Goldman Sachs raised its target price for Argenx from EUR 973.00 to EUR 982.00, maintaining a Buy rating. As of October 5, 2026, the stock was trading at EUR 821.00 at Lang & Schwarz, up 0.56% from the prior close of EUR 816.40. The primary listing is on Nasdaq, where the stock was quoted at USD 919.21 on October 2, 2026, with a 52-week range of USD 661.85 to USD 1,072.75 and a market capitalization of USD 57.2 billion.

For the second quarter of 2026, Argenx reported USD 1.54 billion in revenue and USD 7.32 in earnings per share, exceeding consensus estimates. Revenue beat expectations by USD 90 million, while earnings per share surpassed forecasts by USD 1.46. The next earnings report is scheduled for October 22, 2026, providing another financial checkpoint for the company.

The stock's performance remains below its yearly high, but the positive data and analyst upgrades suggest continued interest in Argenx's neuromuscular pipeline and VYVGART adoption.